Background-Reactive oxygen species (ROS) play an important role in the maintenance of cardiovascular homeostasis. The present study sought to determine whether nuclear factor erythroid-2 related factor 2 (Nrf2), a master gene of the endogenous antioxidant defense system, is a critical regulator of the cardiac hypertrophic response to pathological stress. Methods and Results-Cardiac hypertrophy and dysfunction were established in mice by transverse aortic constriction (TAC). Nrf2 expression was transiently increased and then declined to the basal level while impairment of cardiac function proceeded. The knockout of Nrf2 (Nrf2 Ϫ/Ϫ ) did not cause any apparent structural and functional abnormalities in the unstressed heart. However, Nrf2
I n response to stress from neurohumoral activation, hypertension, or other myocardial injury, the heart initially compensates with an adaptive enlargement of the myocardium (ie, cardiac hypertrophy that is characterized by an increase in the size of individual cardiac myocytes and whole-organ mass). However, sustained cardiac hypertrophy is detrimental and leads to stroke, heart failure, and sudden death. [1] [2] [3] The latest epidemiological data has revealed that cardiac hypertrophy is a major predictor of heart failure, with a mortality as high as 80% for men and 70% for women within 8 years. 4 Despite the prominent contribution of cardiac hypertrophy to heart failure, the molecular mechanisms responsible for the transition from compensated hypertrophy to failure are poorly understood.
It is firmly established that oxidative stress plays a causative role in the pathogenesis of cardiovascular disease including pathological cardiac hypertrophy and heart failure. [5] [6] [7] [8] [9] [10] Surprisingly, larger clinical trials have shown that ROS scavengers of antioxidant vitamins for treatment of cardiovascular disease are ineffective or even harmful. [5] [6] [7] [8] Because these studies have not examined hypertrophic heart disease or heart failure per se, additional studies with specific targeting of the source of oxidative stress or enhancing intrinsic antioxidant pathways are needed. Such studies will not only further extend our understanding of the role of oxidative stress but also potentially lead to therapeutic interventions for the prevention of pathological cardiac hypertrophy.
Nrf2 belongs to the Cap 'n' Collar (CNC) family of basic leucine zipper (bZip) transcription factors that include NF-E2, Nrf1-3, and Bach1-2. [11] [12] [13] Nrf2 is a pleiotropic protein that binds to a cis-acting enhancer sequence known as the antioxidant response element (ARE) with a core nucleotide sequence of 5Ј-RTGACNNNGC-3Ј to control the basal and inducible expression of a battery of antioxidant genes and other cytoprotective phase II detoxifying enzymes, such as heme oxygenase-1 (HO-1), superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione-S-transferases (GST), NAD(P)H:quinone oxidoreductase (NQO1), NQO2, ␥-glutamylcysteine synthase (␥-GCS), and glucuronosyl-transferase. In fact, it has been demonstrated that several Nrf2 target genes, including HO-1, 14,15 SOD, 16 and GPx, 17 protect the heart against maladaptive remodeling. Interestingly, emerging evidence has revealed that Nrf2/ARE signaling plays an important role in preventing oxidative cardiac cell injury in vitro. 18, 19 Nevertheless, the role of Nrf2 in the regulation of cardiac hypertrophy and the prevention of heart failure in vivo remains to be determined.
In the present study, we explore the role of Nrf2 in the pathogenesis of cardiac hypertrophy and subsequent heart failure utilizing Nrf2 knockout (Nrf2 Ϫ/Ϫ ) mice. Our results demonstrate that Nrf2 protects the heart against maladaptive hypertrophic remodeling and failure in response to a sustained pathological hemodynamic stress via the suppression of oxidative stress.
Materials and Methods
Animals, cell culture, adenoviral infection, transverse aortic constriction (TAC) model of pressure overload-induced cardiac hypertrophy and dysfunction, echocardiographic and hemodynamic analysis, RT-PCR and quantitative real-time (Q-PCR), histological, and immunochemical analysis, as well as statistical analysis are detailed in the supplemental Materials and Methods (available online at http://atvb.ahajournals.org).
Results

Upregulation of Nrf2 in Hypertrophied Hearts
To study the potential role of Nrf2 in the pathogenesis of cardiac hypertrophy and heart failure, we initially examined Nrf2 expression profile in murine hypertrophied hearts after TAC, a well-established model of pressure overload-induced cardiac hypertrophy and dysfunction in rodents. In wild-type ICR mice, TAC gradually induced cardiac hypertrophy that was characterized by an increase in the HW/BW ratio and cardiomyocyte size, induction of the atrial natriuretic factor (ANF), and brain natriuretic factor (BNP) fetal genes, and thickening of the diastolic left ventricle posterior wall (LVPWd; supplemental Figure  III ). Cardiac hypertrophy was evident by day 7 and progressive up to the experimental end point of 28 days (supplemental Figure III) . Fractional shortening FS (%) was preserved until day 14 and significantly decreased on day 28 (supplemental Figure III) . Sano et al recently reported similar changes of TAC-induced cardiac hypertrophy and dysfunction in C57BL/6 mice. 20 These results suggest that pressure overload initially induced adaptive hypertrophy (days 1 to 14) with preserved cardiac function; however, this adaptive mechanism could not protect the hypertrophied heart against sustained pressure overload, resulting in maladaptive cardiac remodeling and left ventricular dysfunction (days 14 to 28) in murine TAC model. Interestingly, we observed that TAC caused a transient enhancement of Nrf2 expression at both mRNA and protein levels in the heart. The Nrf2 expression was rapidly increased initially, reached a peak on day 7, and thereafter decreased to near to the basal level on day 28 after TAC (supplemental Figure IVA) . The expression of Nrf2 downstream genes, such as GPx, HO-1, NQO-1, thioredoxin-1 (Txn-1), thioredoxin reductase-1 (Txnrd-1), SOD-2, and SOD-3, was also significantly increased after TAC reaching a peak on day 7 of TAC and thereafter decreasing to a value near to the pre-TAC level on day 28 after TAC (supplemental Figure IVC) . Of note, nuclear translocation of Nrf2 proteins was dramatically enhanced in the cardiomyocytes of hypertrophied hearts after TAC (supplemental Figure IVB) . These results indicate that Nrf2 expression and activity are enhanced during the earlier stage of cardiac adaptive hypertrophy and decreased in the process of maladaptive responses to the sustained hemodynamic stress. Nrf2 might play a critical role in the regulation of maladaptive cardiac remodeling and the transition of cardiac hypertrophy to heart failure.
Characterization of Cardiac Function in Nrf2
؊/؊
Mice at Physiological Normal Status
To further investigate the pathological relevance of Nrf2 signaling, we included Nrf2 Ϫ/Ϫ mice. At 8 weeks of age, Nrf2 deficiency did not cause any apparent structural defects and functional abnormalities in heart (supplemental Figure V and supplemental Table II Figure 1A ). The dead Nrf2 Ϫ/Ϫ mice had apparent signs of heart failure at autopsy (data not shown). Compared to the WT that survived after 2 weeks of TAC, the surviving Nrf2 Ϫ/Ϫ mice exhibited enhanced cardiac hypertrophy, including increases in LVPWd and systolic LV internal dimension (LVIDs) (Figure 1C and D; Table) , and increased lung weight to body weight ratio, an index of heart failure ( Table) , demonstrating a worse pathological ventricular remodeling in Nrf2 Ϫ/Ϫ mice. Most importantly, FS (%) was significantly decreased only in Nrf2 Ϫ/Ϫ mice but not in WT mice ( Figure 1B ), suggesting that loss of Nrf2 function results in earlier onset of cardiac dysfunction in response to pressure overload. Of note, Nrf2 deficiency per se did not affect the blood pressure or heart rate response to pathological pressure overload. After TAC, blood pressure of left and right carotid arteries of WT mice was 96Ϯ4.6 and 141.1Ϯ12.9 mm Hg, respectively, whereas blood pressure of left and right carotid arteries of Nrf2 Ϫ / Ϫ mice was 90Ϯ1.8 and 133.5Ϯ5.9 mm Hg, respectively. TAC induced a similar significant pressure gradient between the right and left carotid arteries in WT (44 mm Hg) and Nrf2 Ϫ/Ϫ (43 mm Hg) mice (supplemental Figure 1) . Echocardiography-derived heart rates of anesthetized (isoflurane) WT and Nrf2
Ϫ/Ϫ mice 2 weeks after TAC were also similar (Pϭ0.09, 384Ϯ44, nϭ10 and 357Ϯ32, nϭ11, respec-tively; supplemental Figure I ). Our results are consistent with previous observations that indicate isoflurane suppresses the basal heart rate and TAC could further induce slight decreases in heart rates (supplemental Figure I ). Taken together, the Nrf2 Ϫ/Ϫ mice that survived 2 weeks had worse cardiomyopathy and overt heart failure after TAC. These results demonstrate that Nrf2 is a critical regulator of adaptive cardiac remodeling, and cardioprotective against the transition to heart failure.
Cardiac Remodeling in Nrf2
؊/؊ Mice After Pathological Pressure Overload Next, we studied the cellular and molecular mechanisms of the maladaptive cardiac responses due to Nrf2 deficiency.
Heart and Myocyte Size
Increased size of hearts is thought to be an adaptive response to increased workload, and inadequate hypertrophy causing heart failure is observed in animal models and patients with aortic stenosis and left ventricular failure. [22] [23] [24] Accordingly, whether inadequate hypertrophy contributes to the worse cardiomyopathy in the Nrf2 Ϫ/Ϫ mice after TAC was determined. As shown in Figure 2A , the Table, Table) . These results demonstrate that the decompensation in Nrf2 Ϫ/Ϫ mice is not attributable to an inappropriate increase in heart or myocyte size per se.
Fetal Gene Induction
Pressure overload and other pathological stresses typically result in the activation of the fetal hypertrophic gene program including an upregulation of ANF, BNP, and ␤-myosin heavy chain (␤MHC), as well as a downregulation of ␣-myosin heavy chain (␣MHC) and sarcoplasmic reticulum calcium ATPase2a (SERCA), which is correlated with pathological ventricular remodeling. 25 The upregulation of ␤MHC expression and downregulation of ␣MHC (␣MHC/␤MHC switch) contribute to the reduction of myofibrillar ATPase activity and cardiac myofiber shortening and velocity of shortening thereby leading to eventual contractile dysfunction. In addition to the ␣MHC/ ␤MHC switch, a downregulation of the gene for encoding the sarcoplasmic reticulum Ca 2ϩ ATPase (SERCA) is involved in pathological myocardial hypertrophy and heart failure. Thus, the role of Nrf2 in regulating fetal hypertrophic gene program was examined by determining the fetal gene expression using Q-PCR. In WT mice, TAC robustly increased the mRNA levels of ANF, BNP, and ␤MHC, and significantly decreased the mRNA levels of ␣MHC and SERCA (supplemental Figure VII and Table) . In Nrf2 Ϫ/Ϫ mice, TAC resulted in a further increase in the mRNAs of ANF, BNP, and ␤MHC as well as a further decrease in the mRNAs of ␣MHC and SERCA (supplemental Figure VII  and Table) . Therefore, the further increase in the ratio of ␣MHC/␤MHC and decrease in SERCA in the heart of Nrf2 Ϫ/Ϫ mice could be a potential link to the overt heart failure in these mice secondary to the pathological pressure overload. In summary, the Nrf2 deficiency exaggerates the pressure overload-induced transcriptional responses by turning on the ␣MHC/␤MHC switch and decreasing SERCA expression that then lead to pathological cardiac hypertrophy and cardiac dysfunction.
Fibrosis
Cardiac fibrosis plays a critical role in the development of abnormal myocardial stiffness and ultimately ventricular dysfunction in response to pathological stimuli. 3 Fibrosis determined by Masson trichrome staining for collagen was negligible in hearts of sham-operated WT and Nrf2 Ϫ/Ϫ mice (Table) . Interstitial fibrosis in WT hearts after TAC was 12.6Ϯ1.57% in the LV free wall endocardium and papillary muscle and 9.8Ϯ1.57% in the base and midportion of the interventricular septum (IVS) which is similar to the findings of others in this model, 26 whereas in the TAC Nrf2 Ϫ/Ϫ hearts it was increased to 24.4Ϯ3.42% of LV free wall) and 20.0Ϯ3.40% of (IVS; supplemental Figure VIII and Table) . Fibrosis in the perivascular area in TAC Nrf2
Ϫ/Ϫ hearts was also larger than that in the TAC WT hearts (data not shown). Collectively, these results indicate that Nrf2 deficiency exaggerates left ventricular fibrosis in response to the pathological pressure overload.
Apoptosis
Because myocardial apoptosis is also a causative factor in cardiomyopathy, 27 we examined the apoptotic changes by TUNEL and cleaved caspase-3 staining in hearts of WT and Nrf2 Ϫ/Ϫ after TAC. In WT hearts 2 weeks after TAC, TUNEL-positive cells were increased 10-fold compared with the sham-operated WT mice (supplemental Figure  IXA and IXB and Table) , similar to the observations of others in this model. 26 In Nrf2
Ϫ/Ϫ hearts after TAC, the apoptotic cells were further increased by about 20-fold compared with the sham-operation (Figure 3 and Table) . Although hearts from sham-operated WT and Nrf2 Ϫ/Ϫ mice had the same numbers of apoptotic cells, a 3-fold increase of myocardial apoptotic cells was observed in the TAC Nrf2
Ϫ/Ϫ hearts compared with the TAC WT hearts (supplemental Figure IXA and IXB and Table) . These observations were further supported by similar changes in caspase-3 activities that were assessed by immunochemical staining of cleaved caspase-3 in the heart sections (supplemental Figure IXC and IXD and Table) . Although the immunochemical staining could not precisely distinguish the apoptotic cell types such as cardiomyocytes or cardiac fibroblasts, these results indicate that Nrf2 deficiency increases overall myocardial apoptosis after pressure overload.
Cardiac Oxidative Stress of Nrf2
؊/؊ Mice After Pathological Pressure Overload
We also investigated the possibility that Nrf2 deficiency exaggerates oxidative stress thereby contributing to the maladaptive cardiac remodeling after pressure overload. Accordingly, we examined oxidative stress status as well as the expression of Nrf2 downstream genes in the hearts of Nrf2 Ϫ/Ϫ mice and their WT littermates after TAC. Myocardial levels of 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation, and 8-hydroxydeoxyguanosine (8-OHdG), a marker of DNA oxidation, 28, 29 were significantly increased in WT mice 2 weeks after TAC ( Figure 3A and 3B), suggesting that pathological pressure overload induces oxidative stress in the heart. Importantly, the TAC-induced oxidative stress was further exaggerated in the hearts of 
Nrf2
Ϫ/Ϫ mice ( Figure 3 ). There were no apparent differences of 4-HNE and 8-OHdG levels in the hearts of sham operated WT and Nrf2 Ϫ/Ϫ mice ( Figure 3 ). These results demonstrate that Nrf2 deficiency leads to increased oxidative stress in the heart secondary to pathological pressure overload. As shown in Figure 3C and supplemental Figure XC through XE, TAC upregulated myocardial expression of HO-1, NQO-1, Txn-1, Txnrd-1, SOD-2, and SOD-3 mRNAs in WT mice but not in Nrf2 Ϫ/Ϫ mice. Also, TAC-induced regulation of PGx was partly inhibited by Nrf2 deficiency ( Figure 3C ). Although TAC did not alter myocardial expression of ␥GCLc in either WT or Nrf2 Ϫ/Ϫ mice, it downregulated myocardial expression of SOD-1 in both WT and Nrf2 Ϫ/Ϫ mice to a similar extent (supplemental Figure XA through XC) . Taken together, these results indicate that endogenous Nrf2 coordinates a group of its downstream antioxidant genes, including GPx, HO-1, NQO-1, Txn-1, Txnrd-1, SOD-2, and SOD-3, to suppress cardiac oxidative stress in the heart in response to pathological pressure overload. 
Role of Nrf2 in the Regulation of Cardiac Myocyte Hypertrophy and Cardiac Fibroblast Proliferation
To further examine the role of Nrf2 in the regulation of cardiac hypertrophy and fibrosis, we applied adenoviral Nrf2 gain-and loss-of-function approaches in cultured cardiac myocytes and fibroblasts. Efficacy of adenoviral overexpression of Nrf2 and Nrf2 shRNA was established in primary cultures of rat neonatal cardiac myocytes and fibroblasts (supplemental Figure II) . Adenoviral overexpression of Nrf2 completely suppressed norepinephrine (NE)-and phenylephrine (PE)-induced ROS production in both cell types, whereas adenoviral overexpression of Nrf2 shRNA dramatically enhanced basal ROS production without further increases in the NE-or PEstimulated cells (Figure 4 and supplemental Figure XIA and XIB). These results indicate that Nrf2 is a critical endogenous suppressor of oxidative stress in both cardiomyocytes and cardiac fibroblasts. In addition, the Nrf2 overexpression inhibited both basal as well as PE-and NE-induced [ 3 H]leucine incorporation and cell size increases in cardiomyocytes ( Figure 5 and supplemental Figure XII) . Moreover, the Nrf2 knockdown enhanced basal cardiomyocyte hypertrophy, whereas it further increased the cardiomyocyte hypertrophy induced by PE and NE ( Figure 5 ). These results suggest that Nrf2 acts as an endogenous inhibitor of cardiomyocyte hypertrophy. On the other hand, not the basal but the PE-and NE-induced cardiac fibroblast proliferation was blocked by the Nrf2 overexpression (supplemental Figure  XIC) . Of interest, the Nrf2 knockdown dramatically enhanced PE-and NE-induced proliferation of cardiac fibroblasts while only slightly increasing the basal proliferation (supplemental Figure XIC) . These results indicate that Nrf2 is an essential negative regulator of cardiac fibroblast proliferation. Because it has been demonstrated that ROS plays a critical role in mediating hypertrophic growth in either cardiomyocytes or cardiac fibroblasts, 10, 30 it is conceivable that Nrf2 inhibits cardiomyocyte hypertrophy and cardiac fibroblast proliferation via the suppression of oxidative stress. Collectively, we have demonstrated that Nrf2 acts as a novel endogenous inhibitor of hypertrophic growth in both cardiomyocytes and cardiac fibroblasts via its ability to suppress oxidative stress.
Discussion
In response to inflammatory or oxidative insults, Nrf2 coordinately upregulates a compensatory transcriptional program that drives the induction of a network of intracellular antioxidative associated pathways and detoxification enzymes, providing a defense against pathological damages including hepatotoxicity, chemical carcinogenesis, pulmonary inflammatory diseases, neurodegenerative diseases, inflammatory and innate immune response, and aging. [11] [12] [13] In the present study, we clearly demonstrate that Nrf2 is a protective regulator that prevents the maladaptive cardiac remodeling and heart failure associated with a sustained pathological hemodynamic stress via at least partly the suppressing of oxidative stress. Of note, Nrf2 deficiency results in an earlier onset of cardiac dysfunction induced by pressure overload. Accordingly, Nrf2 might play a critical role in preventing the transition from compensated to decompensated hypertrophy. Thus our results have provided solid evidence of cardioprotective role of Nrf2 in vivo.
From a mechanistic viewpoint, we have identified several potential cellular mechanisms of the stress-related myocardial abnormalities in Nrf2 Ϫ/Ϫ mice, involving pathological cardiomyocyte hypertrophy, myocardial apoptosis, and fibrosis. Although each of these cellular mechanisms could be predicted from the known actions of Nrf2 in cardiovascular cells, suggesting a direct link between the Nrf2 deficiency and the phenotype, our data have further provided direct evidence to support the notion that Nrf2 orchestrates redox homeostasis for the maintenance of the functional integrity of cardiomyocytes and cardiac fibroblasts, thereby protecting against pathological cardiac remodeling.
It should be noted that a precise molecular mechanism of the Nrf2-mediated cardiac protection has not been fully dissected in the present study. The cause of a more severe cardiac remodeling and dysfunction in Nrf2 Ϫ/Ϫ mice is likely multifactorial, including impaired cardiomyocyte hypertrophy, activated cardiac fibroblasts of a more proliferative and synthetic phenotype, increased cardiac cell apoptosis, and probably enhanced inflammatory responses, because of the following reasons: Firstly, we have demonstrated for the first time that Nrf2 is a novel endogenous inhibitor in the control of cardiomyocyte hypertrophy and cardiac fibroblast proliferation via the regulation of redox status in vitro and Zhu et al have documented that the loss of Nrf2 sensitizes cardiomyocytes and cardiac fibroblasts to oxidative stress-mediated cell death, 18, 19 supporting an antiapoptotic effect of Nrf2 at least for cardiomyocytes and cardiac fibroblasts in the pressure-overloaded heart in vivo. Secondly, whereas Nrf2 is a critical mediator for the resolution of inflammatory and fibrotic responses in lung tissue, 12, 31 it has been demonstrated that chronic cardiac inflammation leads to an altered myocyte phenotype and the activation of matrix metalloproteinases, which results in disruption of interstitial matrix and eventual augmentation of interstitial fibrosis. 32 Therefore, it is conceivable that Nrf2 signaling is critical for suppressing these proinflammatory responses which leads to pathological remodeling of the heart. Thirdly, because it has been demonstrated that genetic background, aging, and gender combined with Nrf2 deficiency contribute to autoimmunity, [33] [34] [35] the gender or aging may influence the Nrf2-mediated cardiac pathophysiology. However, the specific strain of male Nrf2 Ϫ/Ϫ (ICR/Sv129) mice used in our experiments grow normally and do not exhibit any manifestations of illness such as reduced body weight, edema, or cutaneous ulcers. Therefore, it is unlikely that the Nrf2 deficiency-induced detrimental effects on cardiac remodeling in the setting of TAC were related to an altered autoimmunity. Nevertheless, because our results do not specifically exclude the potential impact of Nrf2 on autoimmune-mediated cardiac dysfunction, this issue deserves further investigation using different strains of Nrf2 transgenic mice. Finally, several lines of evidence have recently revealed that cardiac cell interactions, including that between fibroblasts and cardiomyocytes, as well as others such as vascular cells, immune cells, and circulating cardiac progenitor stem cells, are essential for the progression of pathological cardiac remodeling via paracrine or autocrine mechanisms. 36 Of interest, we have observed that increased mortality, cardiac dysfunction, and increased cardiac fibrosis are out of proportion to the slight increase in cardiac hypertrophy in Nrf2 Ϫ/Ϫ mice after pathological pressure overload. Thus, whether the net effect of Nrf2 in regulating cardiac remodeling will be its ability to prevent cardiac fibrosis needs to be further determined.
From a clinical viewpoint, our results emphasize the notion of enhancing endogenous antioxidant systems as a novel therapeutic strategy for the treatment of heart disease. First, our data have demonstrated that Nrf2 expression is transiently upregulated during the earlier stage of cardiac adaptive hypertrophy with preserved cardiac function; however, it decreased in the later stage of maladaptive cardiac remodeling associated with systolic dysfunction. Actually, the activity of antioxidant enzymes is decreased in the human failing hearts. 37 Second, large clinical trials have suggested that the scavenging of ROS using antioxidant therapy for cardiovascular disease is dangerous. [5] [6] [7] [8] Emerging evidence has revealed that the physiological role of ROS is largely neglected and nonselective elimination of ROS is detrimental. 7 In this regard, pharmacological targeting Nrf2 has a great therapeutic potential for the treatment of cardiovascular disease.
In conclusion, our present work demonstrates that Nrf2 is a critical regulator for maintaining structural and functional integrity of the heart that is abnormally stressed. A further dissection of Nrf2-regulated signaling pathways in the heart will provide new perspectives for the rational design and development of a novel class of antioxidative derivatives for the treatment of cardiovascular disease.
